Dr. Rubio’s multinational training and career trajectory have shaped a global perspective on cancer research. His work bridges clinical practice, scientific strategy, and study execution, positioning him as a key contributor to the successful development of next generation of oncology therapies.
His appointment reinforces Theradex Oncology’s commitment to scientific excellence, patient safety, and innovation in cancer drug development.
Gonzalo Rubio states: “I am very excited to join Theradex, a contract research organization (CRO) entirely focused on oncology, a renowned company with a unique vision, expertise, and experience in the development of cancer drugs. It is a privilege to work alongside the Theradex team and combine our expertise to ensure patient safety and medical excellence in the efficient development of cancer therapies.”
Meg Valnoski, CEO at Theradex for more than 20 years, says: “The successful recruitment of Dr. Rubio further strengthens Theradex Oncology’s ability to support our clients’ oncology drug development needs in Europe and globally. Our mission is to ensure that new cancer treatments have the very best opportunity during drug development to demonstrate safety and benefit in patients, with a vision to improve treatment and make cancer a survivable disease. Dr. Rubio will substantially contribute to this mission.”